<DOC>
	<DOCNO>NCT00794703</DOCNO>
	<brief_summary>The objective study compare efficacy safety Mycamine Itraconazole oral solution prevent invasive fungal infection autologous ( malignant blood disease ) allogeneic hematopoietic stem cell transplant patient</brief_summary>
	<brief_title>A Study Compare Efficacy Safety MycamineÂ® Itraconazole Preventing Fungal Infections</brief_title>
	<detailed_description>Dosing Mycamine Itraconazole start begin transplant condition regimen within 48 hour transplant condition regimen , administration time longer 42 day</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Mycoses</mesh_term>
	<mesh_term>Fungemia</mesh_term>
	<mesh_term>Micafungin</mesh_term>
	<mesh_term>Echinocandins</mesh_term>
	<mesh_term>Itraconazole</mesh_term>
	<mesh_term>Hydroxyitraconazole</mesh_term>
	<criteria>Patients risk systemic fungal infection due immunocompromised state due one following : Patient hematologic malignancy undergo autologous hematopoietic stem cell transplant Any patient undergoing allogeneic hematopoietic stem cell transplant Patients moderate severe liver disease , define : AST ALT great 5 time upper limit normal ( ULN ) , OR ; Total bilirubin great 2.5 time ULN Patients evidence deeply invasive disseminate fungal infection time enrollment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Antifungal</keyword>
	<keyword>micafungin</keyword>
	<keyword>itraconazole</keyword>
</DOC>